Duncan R, Kopecková P, Strohalm J, Hume I C, Lloyd J B, Kopecek J
Department of Biological Sciences, University of Keele, Staffordshire, UK.
Br J Cancer. 1988 Feb;57(2):147-56. doi: 10.1038/bjc.1988.31.
DBA2 mice were inoculated i.p. with 10(5)L1210 cells. Animals subsequently treated with daunomycin (single i.p. dose, 0.25-5.0 mg kg-1) all died. The maximum increase in mean survival time observed was approximately 135%. Animals treated with N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers conjugated to daunomycin (DNM) showed a significant increase in mean survival time when the polymer-drug linkage was biodegradable (i.e., Gly-Phe-Leu-Gly). Such treatment also produced a number of long term survivors (greater than 50 days). In contrast, HPMA copolymer conjugated to DNM via a non-degradable linkage (Gly-Gly) produced no increase in survival time relative to untreated control animals. The effect observed with biodegradable HPMA copolymer-DNM conjugates was dependent on the concentration of conjugated drug administered (optimum greater than 5 mg kg-1); the frequency of administration (multiple doses were more effective than single); the timing of administration (single doses given on days 1 and 3 were most effective); and the site of tumour inoculation and route of drug administration. Biodegradable HPMA copolymer-DNM conjugates administered i.p. were active against L1210 inoculated s.c. at higher doses than required to curb a peritoneal tumour. Under certain experimental conditions polymer-DNM conjugates containing fucosylamine or galactosamine proved more active than conjugates without the carbohydrate moeity. The mechanism of drug-conjugate action in vivo is at present unclear. Radioiodination of polymer showed approximately 75% of polymer-drug conjugate to be excreted 24 h after i.p. administration. Synthesis of HPMA conjugates containing [3H]DNM showed that polymer containing Gly-Gly-[3H]DNM was excreted (60% of radioactivity in the urine, 24 h) in macromolecular form. In contrast polymer containing Gly-Phe-Leu-Gly-[3H]DNM was largely excreted in the form of low molecular weight species.
给DBA2小鼠腹腔注射10(5)个L1210细胞。随后用柔红霉素(单次腹腔注射剂量,0.25 - 5.0毫克/千克)治疗的动物全部死亡。观察到的平均存活时间的最大增加约为135%。用与柔红霉素(DNM)偶联的N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物治疗的动物,当聚合物-药物连接键可生物降解时(即甘氨酸-苯丙氨酸-亮氨酸-甘氨酸),平均存活时间显著增加。这种治疗还产生了一些长期存活者(超过50天)。相比之下,通过不可降解连接键(甘氨酸-甘氨酸)与DNM偶联的HPMA共聚物相对于未治疗的对照动物,存活时间没有增加。可生物降解的HPMA共聚物-DNM偶联物观察到的效果取决于给药的偶联药物浓度(最佳浓度大于5毫克/千克);给药频率(多次给药比单次给药更有效);给药时间(第1天和第3天给予单次剂量最有效);以及肿瘤接种部位和药物给药途径。腹腔注射可生物降解的HPMA共聚物-DNM偶联物对皮下接种的L1210有活性,其有效剂量高于抑制腹腔肿瘤所需的剂量。在某些实验条件下,含有岩藻糖胺或半乳糖胺的聚合物-DNM偶联物比不含碳水化合物部分的偶联物更具活性。目前尚不清楚药物-偶联物在体内的作用机制。聚合物的放射性碘化显示,腹腔注射后24小时,约75%的聚合物-药物偶联物被排泄。含有[3H]DNM的HPMA偶联物的合成表明,含有甘氨酸-甘氨酸-[3H]DNM的聚合物以大分子形式排泄(24小时内60%的放射性在尿液中)。相比之下,含有甘氨酸-苯丙氨酸-亮氨酸-甘氨酸-[3H]DNM的聚合物主要以低分子量物质的形式排泄。